



2013 Physician Quality Reporting System (PQRS) Measure-Applicability Validation (MAV) Process

03/04/13

2013 PQRS MEASURE-APPLICABILITY VALIDATION (MAV) PROCESS FOR CLAIMS-BASED REPORTING OF INDIVIDUAL MEASURES

The 2013 Physician Quality Reporting System (PQRS) incentive eligibility will include validation processes. Under the claims-based reporting method of individual measure(s), the determination of satisfactory reporting will itself serve as a general validation because the analysis will assess whether quality-data codes (QDCs) are appropriately submitted in a sufficient proportion of the instances when a reporting opportunity exists. In addition, for those eligible professionals who satisfactorily submit QDCs for fewer than three PQRS measures, a measure-applicability validation (MAV) process will determine whether they should have submitted QDCs for additional measures.

CMS will apply a two-step process to operationalize measure-applicability validation: (1) a "clinical relation" test, and (2) a "minimum threshold" test. Those who fail the validation process will not earn the PQRS incentive payment for 2013. Eligible professionals who fail MAV could still avoid the 2015 Payment Adjustment. Please refer to the PQRS Payment Adjustment documentation on the CMS website at <http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/PQRS>.

CMS may determine that it is necessary to modify the measure-applicability validation process after the start of the 2013 reporting period. However, any changes will result in the process being applied more leniently, thereby (1) allowing a greater number of eligible professionals to pass validation and (2) causing no eligible professional who would otherwise have passed to fail.

Prerequisites for Measure-Applicability Validation

Eligible professionals who submit QDCs for **only one or only two** PQRS measures for at least 50 percent of their patients or encounters eligible for each measure and who do not submit **any** QDCs for **any other** measure will be subject to the measure-applicability validation process. Selection of eligible professionals for measure-applicability validation may be accomplished through a sampling mechanism.

Step 1: Clinical Relation Test

The clinical relation test is the first step in the two-step measure-applicability validation that will be applied to those who are subject to the validation process. This test is based on: (1) an extension of the statutory presumption that if an eligible professional submits data for a measure, then that measure applies to her/his practice and (2) the concept that if one measure in a cluster of measures related to a particular clinical topic or eligible professional service is applicable to an eligible professional's practice, then other closely-related measures (measures in that same cluster) **may** also be applicable.

The following is an example of how the clinical relation test will be applied: An eligible professional who is subject to measure-applicability validation submitted QDCs for one of the PQRS measures related to pneumonia. The eligible professional's claims will then be analyzed using the minimum threshold test described below in Step 2 to determine whether another pneumonia measure (or two more pneumonia measures) could also have been submitted.

The list of clusters of related measures and the PQRS measures that are included within each cluster are presented below. CMS may determine this list should be modified to apply the measure-applicability validation process more leniently. Any such modifications will be published on the CMS PQRS website as soon as possible after a determination has been made.

**2013 PQRS MEASURE-APPLICABILITY VALIDATION (MAV)
PROCESS FOR CLAIMS-BASED REPORTING
OF INDIVIDUAL MEASURES**

**Clusters of Clinically Related Measures Used in Step 1 of the 2013
PQRS Measure-Applicability Validation for Claims-Based Reporting of Individual Measures**

Cluster Number	Cluster Title	Measure Number	Measure Title
1	General Preventive Care	128	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up
		226	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
		317	Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented
2	Preventive Care for Women	39	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older
		48	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older
		112	Preventive Care and Screening: Breast Cancer Screening
3	Diabetic Care	1	Diabetes Mellitus: Hemoglobin A1c Poor Control
		2	Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control
		3	Diabetes Mellitus: High Blood Pressure Control
		119	Diabetes Mellitus: Medical Attention for Nephropathy
4	COPD Care	51	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation
		52	Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy
5	Asthma Care	53	Asthma: Pharmacologic Therapy for Persistent Asthma – Ambulatory Care Setting
		64	Asthma: Assessment of Asthma Control – Ambulatory Care Setting
		231	Asthma: Tobacco Use: Screening - Ambulatory Care Setting
		232	Asthma: Tobacco Use: Intervention - Ambulatory Care Setting
6	Pneumonia Care	56	Emergency Medicine: Community-Acquired Pneumonia (CAP): Vital Signs
		59	Emergency Medicine: Community-Acquired Pneumonia (CAP): Empiric Antibiotic

**2013 PQRS MEASURE-APPLICABILITY VALIDATION (MAV)
PROCESS FOR CLAIMS-BASED REPORTING
OF INDIVIDUAL MEASURES**

Cluster Number	Cluster Title	Measure Number	Measure Title
7	Cancer Care 1	67	Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow
		68	Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy
		69	Hematology: Multiple Myeloma: Treatment with Bisphosphonates
		70	Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry
8	Cancer Care 2	72	Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients
		194	Oncology: Cancer Stage Documented
9	Breast Cancer Care	71	Breast Cancer: Hormonal Therapy for Stage IC - IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast cancer
		262	Image Confirmation of Successful Excision of Image-Localized Breast Lesion
		263	Preoperative Diagnosis of Breast Cancer
10	Urinary Incontinence Care	49	Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older
		50	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older
11	Fracture Follow-Up Care	24	Osteoporosis: Communication with the Physician Managing On-Going Care Post-Fracture of Hip, Spine, or Distal Radius for Men and Women Aged 50 Years and Older
		40	Osteoporosis: Management Following Fracture of Hip, Spine, or Distal Radius for Men and Women Aged 50 Years and Older
12	Ear, Nose, Throat Care	91	Acute Otitis Externa (AOE): Topical Therapy
		93	Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use
13	Pediatric Ear, Nose, Throat Care	65	Appropriate Treatment for Children with Upper Respiratory Infection (URI)
		66	Appropriate Testing for Children with Pharyngitis

**2013 PQRS MEASURE-APPLICABILITY VALIDATION (MAV)
PROCESS FOR CLAIMS-BASED REPORTING
OF INDIVIDUAL MEASURES**

Cluster Number	Cluster Title	Measure Number	Measure Title
14	Emergency Care	28	Aspirin at Arrival for Acute Myocardial Infarction (AMI)
		54	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain
		55	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Syncope
		252	Anticoagulation for Acute Pulmonary Embolus Patients
		254	Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain
		255	Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure
15	Pathology	99	Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade
		100	Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade
		249	Barrett's Esophagus
		250	Radical Prostatectomy Pathology Reporting
		251	Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients
16	Diagnostic Imaging	145	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy
		146	Radiology: Inappropriate Use of "Probably Benign" Assessment Category in Mammography Screening
		147	Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy
		225	Radiology: Reminder System for Mammograms
17	Depression	9	Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD
		106	Adult Major Depressive Disorder (MDD): Comprehensive Depression Evaluation: Diagnosis and Severity
		107	Adult Major Depressive Disorder (MDD): Suicide Risk Assessment
18	Eye Care 1	12	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation
		141	Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care
19	Eye Care 2	18	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy
		19	Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care

**2013 PQRS MEASURE-APPLICABILITY VALIDATION (MAV)
PROCESS FOR CLAIMS-BASED REPORTING
OF INDIVIDUAL MEASURES**

Cluster Number	Cluster Title	Measure Number	Measure Title
20	Eye Care 3	14	Age-Related Macular Degeneration (AMD): Dilated Macular Examination
		140	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement
21	Hepatitis Care	84	Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment
		85	Hepatitis C: HCV Genotype Testing Prior to Treatment
		86	Hepatitis C: Antiviral Treatment Prescribed
		87	Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment
		89	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption
		90	Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Treatment
		183	Hepatitis C: Hepatitis A Vaccination in Patients with HCV
		184	Hepatitis C: Hepatitis B Vaccination in Patients with HCV
22	Renal Disease Care	121	Adult Kidney Disease: Laboratory Testing Lipid Profile
		122	Adult Kidney Disease: Blood Pressure Management
		123	Adult Kidney Disease: Patients on Erythropoiesis-Stimulating Agents (ESA) Hemoglobin Level > 12.0 g/dL
23	Stroke Management	31	Stroke and Stroke Rehabilitation: Deep Vein Thrombosis (DVT) Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage
		35	Stroke and Stroke Rehabilitation: Screening for Dysphagia
24	Stroke Discharge	32	Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy
		36	Stroke and Stroke Rehabilitation: Rehabilitation Services Ordered
25	Surgical Care	20	Perioperative Care: Timing of Prophylactic Parenteral Antibiotic – Ordering Physician
		21	Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second Generation Cephalosporin
		22	Perioperative Care: Discontinuation of Prophylactic Parenteral Antibiotics (Non-Cardiac Procedures)
		23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)

**2013 PQRS MEASURE-APPLICABILITY VALIDATION (MAV)
PROCESS FOR CLAIMS-BASED REPORTING
OF INDIVIDUAL MEASURES**

Cluster Number	Cluster Title	Measure Number	Measure Title
26	Cardiac Surgical Care	43	Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery
		44	Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery
		45	Perioperative Care: Discontinuation of Prophylactic Parenteral Antibiotics (Cardiac Procedures)
27	Diabetic Foot Care	126	Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy – Neurological Evaluation
		127	Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention – Evaluation of Footwear
28	Osteoarthritis Care	109	Osteoarthritis (OA): Function and Pain Assessment
		142	Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications
29	Rheumatoid Arthritis Care	108	Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
		176	Rheumatoid Arthritis (RA): Tuberculosis Screening
		177	Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity
		178	Rheumatoid Arthritis (RA): Functional Status Assessment
		179	Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis
		180	Rheumatoid Arthritis (RA): Glucocorticoid Management
30	Falls	154	Falls: Risk Assessment
		155	Falls: Plan of Care
31	Anesthesia Care 1	30	Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics
		76	Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol
			<i>When reporting #76 alone, it is not subject to MAV</i>
32	Anesthesia Care 2	76	Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol
		193	Perioperative Temperature Management
			<i>When reporting #76 alone, it is not subject to MAV</i>

**2013 PQRS MEASURE-APPLICABILITY VALIDATION (MAV)
PROCESS FOR CLAIMS-BASED REPORTING
OF INDIVIDUAL MEASURES**

Cluster Number	Cluster Title	Measure Number	Measure Title
33	Ear Care	188	Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear
		261	Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness
34	Ischemic Vascular Disease	201	Ischemic Vascular Disease (IVD): Blood Pressure Management
		241	Ischemic Vascular Disease (IVD): Complete Lipid Profile and Low Density Lipoprotein (LDL-C) Control
		204	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic
35	Chronic Wound Care	245	Chronic Wound Care: Use of Wound Surface Culture Technique in Patients with Chronic Skin Ulcers Overuse Measure
		246	Chronic Wound Care: Use of Wet to Dry Dressings in Patients with Chronic Skin Ulcers Overuse Measure
36	Epilepsy Care	266	Epilepsy: Seizure Types(s) and Current Seizure Frequency(ies)
		267	Epilepsy: Documentation of Etiology of Epilepsy or Epilepsy Syndrome
		268	Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy
37	Substance Use Disorders	247	Substance Use Disorders: Counseling Regarding Psychosocial and Pharmacologic Treatment Options for Alcohol Dependence
		248	Substance Use Disorders: Screening for Depression Among Patients with Substance Abuse or Dependence.
38	Immunization	110	Preventive Care and Screening: Influenza Immunization
		111	Preventive Care and Screening: Pneumococcal Vaccination for Patients 65 Years and Older
39	Endoscopy and Polyp Surveillance	185	Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use
		320	Endoscopy/Polyp Surveillance: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients
40	Pediatric Renal Disease Care	327	Pediatric Kidney Disease: Adequacy of Volume Management
		328	Pediatric Kidney Disease: ESRD Patients receiving Dialysis: Hemoglobin Level < 10g/dL

Measures Not Included Within a Cluster in 2013 PQRS

For 2013 measure-applicability validation, CMS will not include measures that are deemed to be generally or broadly applicable to all or many Medicare patients and, therefore, potentially unreasonable to attribute to individual eligible professionals using claims-based data. Other measures are not included in a cluster of closely clinically related measures for other clinical or technical reasons, such as: (1) the measure may not fit any cluster; or (2) the measure may fit reasonably with more than one cluster.

2013 PQRS MEASURE-APPLICABILITY VALIDATION (MAV) PROCESS FOR CLAIMS-BASED REPORTING OF INDIVIDUAL MEASURES

Measures excluded from 2013 measure-applicability validation for claims-based participation may or may not be included in groupings of measures used in validation protocols for other mechanisms of data submission, such as those based on extracts from medical registries or electronic health records, or for other purposes or programs.

Based on such developments as refinements to a particular measure's specifications or enhancements of the PQRS list of available claims-based measures, any measure excluded from measure-applicability validation for 2013 may also, in subsequent program years, be included in a measure-applicability validation for claims-based participation in PQRS.

At a minimum, the following claim-based measures will be excluded from measure-applicability validation for 2013:

Measure 6	Coronary Artery Disease (CAD): Antiplatelet Therapy
Measure 41	Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older
Measure 46	Medication Reconciliation
Measure 47	Advance Care Plan
Measure 102	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients
Measure 104	Prostate Cancer: Adjuvant Hormonal Therapy for High Risk Prostate Cancer Patients
Measure 113	Preventive Care and Screening: Colorectal Cancer Screening
Measure 116	Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use
Measure 117	Diabetes Mellitus: Dilated Eye Exam
Measure 130	Documentation of Current Medications in the Medical Record
Measure 131	Pain Assessment and Follow-Up
Measure 134	Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan
Measure 156	Oncology: Radiation Dose Limits to Normal Tissues
Measure 157	Thoracic Surgery: Recording of Clinical Stage Prior to Lung Cancer or Esophageal Cancer Resection
Measure 163	Diabetes Mellitus: Foot Exam
Measure 172	Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula
Measure 173	Preventive Care and Screening: Unhealthy Alcohol Use – Screening
Measure 181	Elder Maltreatment Screen and Follow-Up Plan
Measure 182	Functional Outcome Assessment
Measure 195	Radiology: Stenosis Measurement in Carotid Imaging Reports
Measure 236	Hypertension (HTN): Controlling High Blood Pressure
Measure 321	Participation by a Hospital, Physician or Other Clinician in a Systematic Clinical Database Registry that Includes Consensus Endorsed Quality Measures
Measure 326	Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy

Prior to performing the analysis to determine satisfactory reporting, CMS may determine that additional PQRS measures should be excluded from measure-applicability validation. Any additions to this list will be published on the CMS PQRS website as soon as possible after a determination has been made.

2013 PQRS MEASURE-APPLICABILITY VALIDATION (MAV) PROCESS FOR CLAIMS-BASED REPORTING OF INDIVIDUAL MEASURES

Step 2: Minimum Threshold Test

This second step will be applied to those who are subject to measure-applicability validation and who have potential additional measures that could have been submitted identified during the clinical relation test.

The minimum threshold test is based on the concept that during the 2013 reporting period January 1, 2013 through December 31, 2013, if an eligible professional treated more than a certain number of Medicare patients with a condition to which a certain measure applied (that is, the eligible professional treated more than a "threshold" number of patients or encounters), then that eligible professional should be accountable for submitting the QDC(s) for that measure. The common minimum threshold, based on statistical and clinical frequency considerations, will not be less than 15 patients (or encounters) for the 12-month reporting period for each 2013 PQRS measure.

The following are examples of how the minimum threshold test will be applied: An emergency department physician treated 20 Medicare patients with pneumonia during the 12-month reporting period for 2013. If that emergency department physician is subject to validation and was found to have submitted a QDC for at least one of the pneumonia measures under the clinical relation test, then the physician would be deemed responsible for submitting QDCs for at least one other PQRS pneumonia measure and will not earn the 2013 incentive payment. Alternatively, if an internist was subject to validation and was found to have submitted a QDC for at least one of the pneumonia measures under the clinical relation test, but treated only two Medicare patients with pneumonia during the same period, then the internist would not be responsible for submitting the additional pneumonia measures and would not be precluded from receiving an incentive payment.

During the reporting period, CMS will determine a minimum threshold for each individual PQRS measure based on analysis of Part B claims data. However, no threshold will fall below the common threshold of 15 patients (or encounters) described above.

Other Program Integrity Considerations

QDCs submitted on claims must be supported in medical record documentation. Other laws and regulations relating to Medicare program integrity may also apply to PQRS.

Measures Reported via Registry or Measures Group Only – Not Applicable to MAV

The following list of measures will be reported through registries or by measure group reporting only, therefore, are not subject to measure-applicability validation.

Measure 5	Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
Measure 7	Coronary Artery Disease (CAD): Beta-Blocker Therapy - Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%)
Measure 8	Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
Measure 33	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation (AF) at Discharge
Measure 81	Adult Kidney Disease: Hemodialysis Adequacy: Solute
Measure 82	Adult Kidney Disease: Peritoneal Dialysis Adequacy: Solute
Measure 83	Hepatitis C: Testing for Chronic Hepatitis C – Confirmation of Hepatitis C Viremia
Measure 118	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%)
Measure 137	Melanoma: Continuity of Care-Recall System
Measure 138	Melanoma: Coordination of Care

**2013 PQRS MEASURE-APPLICABILITY VALIDATION (MAV)
PROCESS FOR CLAIMS-BASED REPORTING
OF INDIVIDUAL MEASURES**

Measure 143	Oncology: Medical and Radiation – Pain Intensity Quantified
Measure 144	Oncology: Medical and Radiation – Plan of Care for Pain
Measure 148	Back Pain: Initial Visit
Measure 149	Back Pain: Physical Exam
Measure 150	Back Pain: Advice for Normal Activities
Measure 151	Back Pain: Advice Against Bed Rest
Measure 159	HIV/AIDS: CD4+ Cell Count or CD4+ Percentage
Measure 160	HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis
Measure 161	HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy
Measure 162	HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy
Measure 164	Coronary Artery Bypass Graft (CABG): Prolonged Intubation
Measure 165	Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate
Measure 166	Coronary Artery Bypass Graft (CABG): Stroke
Measure 167	Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure
Measure 168	Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration
Measure 169	Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at Discharge
Measure 170	Coronary Artery Bypass Graft (CABG): Beta-Blockers Administered at Discharge
Measure 171	Coronary Artery Bypass Graft (CABG): Anti-Lipid Treatment at Discharge
Measure 187	Stroke and Stroke Rehabilitation: Thrombolytic Therapy
Measure 191	Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery
Measure 192	Cataracts: Complication within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures
Measure 197	Coronary Artery Disease (CAD): Lipid Control
Measure 198	Heart Failure: Left Ventricular Ejection Fraction (LVEF) Assessment
Measure 205	HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia and Gonorrhea
Measure 208	HIV/AIDS: Sexually Transmitted Disease Screening for Syphilis
Measure 209	Functional Communication Measure - Spoken Language Comprehension
Measure 210	Functional Communication Measure – Attention
Measure 211	Functional Communication Measure – Memory
Measure 212	Functional Communication Measure - Motor Speech
Measure 213	Functional Communication Measure – Reading
Measure 214	Functional Communication Measure – Spoken Language Expression
Measure 215	Functional Communication Measure – Writing
Measure 216	Functional Communication Measure – Swallowing
Measure 217	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Knee Impairments
Measure 218	Functional Deficit: Change in Risk- Adjusted Functional Status for Patients with Hip Impairments
Measure 219	Functional Deficit: Change in Risk- Adjusted Functional Status for Patients with Lower Leg, Foot or Ankle Impairments
Measure 220	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lumbar Spine Impairments
Measure 221	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Shoulder Impairments
Measure 222	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Elbow, Wrist or Hand Impairments
Measure 223	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Neck, Cranium, Mandible, Thoracic Spine, Ribs, or Other General Orthopedic Impairments

**2013 PQRS MEASURE-APPLICABILITY VALIDATION (MAV)
PROCESS FOR CLAIMS-BASED REPORTING
OF INDIVIDUAL MEASURES**

Measure 224	Melanoma: Overutilization of Imaging Studies in Melanoma
Measure 228	Heart Failure (HF): Left Ventricular Function (LVF) Testing
Measure 233	Thoracic Surgery: Recording of Performance Status Prior to Lung or Esophageal Cancer Resection
Measure 234	Thoracic Surgery: Pulmonary Function Tests Before Major Anatomic Lung Resection (Pneumonectomy, Lobectomy, or Formal Segmentectomy)
Measure 242	Coronary Artery Disease (CAD): Symptom Management
Measure 243	Cardiac Rehabilitation Patient Referral from an Outpatient Setting
Measure 244	Hypertension: Blood Pressure Management
Measure 256	Surveillance after Endovascular Abdominal Aortic Aneurysm Repair (EVAR)
Measure 257	Statin Therapy at Discharge after Lower Extremity Bypass (LEB)
Measure 258	Rate of Open Repair of Small or Moderate Non-Ruptured Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #7)
Measure 259	Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home Post-Operative Day #2)
Measure 260	Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home Post-Operative #2)
Measure 264	Sentinel Lymph Node Biopsy for Invasive Breast Cancer
Measure 265	Biopsy Follow-Up
Measure 269	Inflammatory Bowel Disease (IBD): Type, Anatomic Location and Activity All Documented
Measure 270	Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Sparing Therapy
Measure 271	Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Related Iatrogenic Injury – Bone Loss Assessment
Measure 272	Inflammatory Bowel Disease (IBD): Preventive Care: Influenza Immunization
Measure 273	Inflammatory Bowel Disease (IBD): Preventive Care: Pneumococcal Immunization
Measure 274	Inflammatory Bowel Disease (IBD): Testing for Latent TB Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy
Measure 275	Inflammatory Bowel Disease (IBD): Assessment of Hepatitis B Virus (HBV) Status Before Initiating Anti-TNF (Tumor Necrosis Factor) Therapy
Measure 276	Sleep Apnea: Assessment of Sleep Symptoms
Measure 277	Sleep Apnea: Severity Assessment at Initial Diagnosis
Measure 278	Sleep Apnea: Positive Airway Pressure Therapy Prescribed
Measure 279	Sleep Apnea: Assessment of Adherence to Positive Airway Pressure Therapy
Measure 280	Dementia: Staging of Dementia
Measure 281	Dementia: Cognitive Assessment
Measure 282	Dementia: Functional Status Assessment
Measure 283	Dementia: Neuropsychiatric Symptom Assessment
Measure 284	Dementia: Management of Neuropsychiatric Symptoms
Measure 285	Dementia: Screening for Depressive Symptoms
Measure 286	Dementia: Counseling Regarding Safety Concerns
Measure 287	Dementia: Counseling Regarding Risks of Driving
Measure 288	Dementia: Caregiver Education and Support
Measure 289	Parkinson's Disease: Annual Parkinson's Disease Diagnosis Review
Measure 290	Parkinson's Disease: Psychiatric Disorders or Disturbances Assessment
Measure 291	Parkinson's Disease: Cognitive Impairment or Dysfunction Assessment
Measure 292	Parkinson's Disease: Querying about Sleep Disturbances
Measure 293	Parkinson's Disease: Rehabilitative Therapy Options
Measure 294	Parkinson's Disease: Parkinson's Disease Medical and Surgical Treatment Options Reviewed

**2013 PQRS MEASURE-APPLICABILITY VALIDATION (MAV)
PROCESS FOR CLAIMS-BASED REPORTING
OF INDIVIDUAL MEASURES**

Measure 295	Hypertension: Appropriate Use of Aspirin or Other Antithrombotic Therapy
Measure 296	Hypertension: Complete Lipid Profile
Measure 297	Hypertension: Urine Protein Test
Measure 298	Hypertension: Annual Serum Creatinine Test
Measure 299	Hypertension: Diabetes Mellitus Screening Test
Measure 300	Hypertension: Blood Pressure Control
Measure 301	Hypertension: Low Density Lipoprotein (LDL-C) Control
Measure 302	Hypertension: Dietary and Physical Activity Modifications Appropriately Prescribed
Measure 303	Cataracts: Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery
Measure 304	Cataracts: Patient Satisfaction within 90 Days following Cataract Surgery
Measure 322	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients
Measure 323	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI)
Measure 324	Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low Risk Patients
Measure 325	Adult Major Depressive Disorder (MDD): Coordination of Care of Patients with Specific Comorbid Conditions